Description: Anti-obesity medications have been met with reluctance from payers and employee benefits consultants who often lack analogs or empirical data to estimate the cost impact of new therapies coverage. Health plans considering coverage of anti-obesity medications will need to assess and manage the potential costs of covering these new therapies in context of their overall obesity management strategy, including coverage of nutrition counseling, weight management, and bariatric surgery.

Description: Renal disease is a very heterogenous medical condition whose end state is dialysis, a recurring cost intensive medical condition. Dialysis cost is one of the major medical cost drivers in USA. Insufficient and improper care management in the early stages of CKD (chronic kidney disease) leads to early incidence of end stage renal disease (ESRD) among CKD patients which not only leads to high medical costs, but also reflects poor health quality.

Description: CMS has required hospitals to publish their chargemaster rates, cash discounts and negotiated rates as of January 1, 2021. Our panel is comprised of a data strategist, an executive from a large hospital system and an actuary.

Description: With mortality rates significantly higher in 2020 and 2021 due to the COVID-19 pandemic, actuaries that rely on historical experience cannot properly craft assumptions about the future due to the recent excess deaths. This webcast focuses on the practicality of using pandemic mortality experience, as well as how to overcome the practical challenges of that data implementation. Explore an overview of different approaches used by institutions in the U.S., Canada and UK and an observation of industry survey responses. There will also be a comparison to recent SOA expert opinion surveys and short term impacts on the future of U.S. mortality.

Description: This session will explore the evolving landscape of accident and health valuation, with a special focus on GAAP Long Duration Targeted Improvements. Discussion will delve into the intricacies of change brought by GAAP LDTI for calculation of both Lifetime Future Policy Benefits (LFPB) and Deferred Acquisition Costs, as well as potential downstream impacts to other activities related to general GAAP and STAT reserving such as experience analysis, model system conversion, financial planning and analysis, and statutory margin analysis. Attendees should be able to connect accounting and financial reporting concepts under GAAP LDTI to opportunities for technology modernization, improved transparency of financial analytics, and important considerations unique to Accident and Health products.

Description: In this talk, we look at two behavioral aspects: from end customers perspective and through the lens of underwriters. We will examine simple rules to improve the insurance underwriting decision to judge whether a risk is insurable and whether they have impact on increasing underwriting decision quality.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: "This talk will evaluate the present pace of evolution in actuarial data management due to economic and demographic pressures, evolving regulatory/compliance requirements, AI and the growing need to have advanced analytic capabilities. We will evaluate each factor briefly to isolate their impact on actuarial data management, highlighting risks and opportunities for actuaries and IT teams supporting actuaries. Attendees will gain insights into the factors affecting changes in actuarial data technologies, understand key differences between centralized and decentralized data management approaches, including their impact on data quality, governance, performance, and scalability. The session will highlight some pain points of centralization, such as the integration of actuarial transformation initiatives with IT processes, juggling data complexity and business logic, and the limited creativity and agility due to interdependencies between components and evaluate how emerging concepts such as actuarial data stores tackle the 'centralization' problem. We will also cover a real-life use case covering the evolution of actuarial data management and challenges identified in previous parts of the presentation. The session will avoid going into any specific solution details: it will address current challenges due to broad shifts, then evaluate newer concepts, corresponding risks and opportunities. - Understand key macro and micro drivers impacting actuarial data management - Understand centralized and decentralized approaches to actuarial data management - Evaluate the concept of an actuarial data store - Coordinate better with IT teams to deliver changing actuarial data technology needs"

Description: In this session, attendees will understand the role of AI in risk management and underwriting. You will see insightful case studies highlighting AI-driven techniques for enhancing precision and efficiency in these areas. Additionally, the session will cover advanced AI applications in claim management and fraud detection, showcasing cutting-edge strategies to mitigate risks and streamline operations.

Description: Understanding Asian Capital Regimes